Cough Management in Coronary Artery Disease

Primary Recommendations

• The American College of Cardiology recommends benzonatate as the preferred antitussive for patients with coronary artery disease (CAD) requiring cough suppression, with precautions including starting at the lowest effective dose and monitoring for interactions with beta-blockers and nitrates 1
• The European Society of Cardiology suggests exercising caution with beta-blocker combinations due to potential additive effects on cardiac conduction, particularly in CAD patients with angina 2, 1

Pharmacological Interventions

• The American Heart Association recommends starting benzonatate at the lowest effective dose, typically 100 mg three times daily, and limiting the duration of therapy to minimize cardiovascular risks 1
• The European Heart Journal advises monitoring for nitrate interactions, as these medications are commonly used for anginal symptom control in CAD patients 1
• The American College of Cardiology recommends avoiding dextromethorphan combinations with medications that affect cardiac conduction without specific guidance 1

Non-Pharmacological Approaches

• The European Respiratory Society suggests prioritizing hydration and humidification as initial interventions before pharmacological cough suppression 1
• The American College of Radiology recommends addressing underlying cardiac optimization by ensuring adequate control of angina and heart failure symptoms, as venous congestion from poor cardiac function can cause cough 5

Patient Monitoring and Education

• The American Heart Association recommends assessing baseline angina frequency and severity to establish a reference point for detecting changes, and reviewing the complete medication list for potential interactions 1
• The European Society of Cardiology advises monitoring for new or worsening anginal symptoms, and watching for changes in heart rate or rhythm, particularly in patients on beta-blockers or non-dihydropyridine calcium channel blockers 1
• The American College of Cardiology recommends instructing patients to report immediately any new chest pain, increased angina frequency, or worsening cardiac symptoms while taking benzonatate 1

Critical Considerations

• The European Heart Journal emphasizes the importance of continued adherence to essential CAD medications, such as antiplatelet agents, statins, beta-blockers, and ACE inhibitors/ARBs, as these reduce cardiovascular mortality and must not be interrupted 3, 1
• The American College of Radiology warns against overlooking cardiac causes of cough, such as pulmonary congestion from decompensated heart failure or left atrial enlargement 5